Difference between revisions of "Daunorubicin (Cerubidine)"
(updated content) |
|||
| Line 11: | Line 11: | ||
*[[Acute lymphocytic leukemia]] | *[[Acute lymphocytic leukemia]] | ||
*[[Acute myeloid leukemia]] | *[[Acute myeloid leukemia]] | ||
| + | *[[Acute promyelocytic leukemia]] | ||
==Patient drug information== | ==Patient drug information== | ||
Revision as of 14:55, 19 June 2013
Also known as daunomycin, daunomycin cerubidine, daunorubicin hydrochloride, or rubidomycin hydrochloride.
General information
Class/mechanism: Anthracycline, binds and intercalates between DNA base pairs. Inhibits topoisomerase II activity by stabilizing the DNA-topoisomerase II complex, resulting in single and double strand DNA breaks. May also inhibit polymerase activity and trigger free radical damage to DNA.[1][2]
Route: IV
Extravasation: vesicant
For conciseness and simplicity, HemOnc.org currently will focus on treatment regimens and not list information such as: renal/hepatic dose adjustments, metabolism (including CYP450), excretion, monitoring parameters (although this will be considered for checklists), or manufacturer. Instead, for the most current information, please refer to your preferred pharmacopeias such as Micromedex, Lexicomp, UpToDate (courtesy of Lexicomp), or the prescribing information.[1]
Diseases for which it is used
Patient drug information
- Daunorubicin (Cerubidine) patient drug information (Chemocare)[3]
- Daunorubicin (Cerubidine) patient drug information (UpToDate)[4]